- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02232373
Campylobacter Enteritis and PI-BD: Dietary Reduction in Carbohydrates (CEDRIC)
A Pilot Double Blind, Randomised, Placebo Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Symptoms of Post-infective Bowel Dysfunction
The purpose of the study is explore the issues that relate to testing a particular dietary treatment, the low FODMAP diet, in a randomised trial using an appropriate control diet with which to compare it. In this trial the investigators will look at its effect on symptoms of people with persistent disturbance in their bowel pattern 3 months after an intestinal infection with Campylobacter.
The investigators will also look at the changes in gut bacteria that occur with the diet.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nottingham, United Kingdom, NG7 2UH
- University of Nottingham
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participation in the CERAMIC study (see linked protocol)
- On-going post infective bowel dysfunction (PI-BD) 3 months after confirmation of Campylobacter spp. in stool sample. This is defined as responding 'No' to the question "have your bowels returned to normal since your Campylobacter infection?"
- Will consent to use of data and samples acquired for CERAMIC in the analysis of CEDRIC
Exclusion Criteria:
As for CERAMIC study (so already confirmed)
- Pregnancy declared by the candidate
- History declared by the candidate of pre-existing gastrointestinal disorder, including but not limited to: Inflammatory Bowel Disease; Coeliac Disease; Pancreatitis; Gallstone disease (biliary colic, cholecystitis); Diverticulitis; Cancer of the gastrointestinal tract; Irritable Bowel Syndrome
- Reported history of previous resection of any part of the gastrointestinal tract other than appendix or gallbladder
- Intestinal stoma
- Habitual use of opiate analgesics likely to alter bowel function e.g. morphine
- Use of antibiotics in the preceding four weeks other than for treatment of index infection. Any condition where the candidate is likely to require a course of antibiotics in the next 3 months e.g. severe chronic respiratory disease, recurrent urinary tract infection, lower limb ulceration
- Inability to complete the symptom questionnaires e.g. cognitive dysfunction, limiting memory and understanding
- Anyone who in the opinion of the investigator is unlikely to be able to comply with the protocol e.g. cognitive dysfunction, chaotic lifestyle related to substance abuse
Addition criteria for CEDRIC study:
- Use of antibiotics or prescribed probiotics during the CERAMIC study
- Failure to provide research stool samples during CERAMIC study
- Dietary practice not compatible with safe implementation of the trial diet e.g.veganism
- Medical reasons for pre-existing controlled diet that cannot be safely randomised e.g. end-stage kidney disease, diabetes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
SHAM_COMPARATOR: Normal FODMAP arm
Low FODMAP dietary advice; participants to supplement diet with oligofructose, a poorly digested carbohydrate that will restore FODMAP content to the diet.
|
An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet.
Second session after one month on re-introduction of FODMAP containing foods.
Dietary supplementation with oligofructose 5 grams twice daily for a month
Other Names:
|
EXPERIMENTAL: Low FODMAP arm
Low FODMAP dietary advice; participants to supplement with maltodextrin (easily digestible carbohydrate)
|
An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet.
Second session after one month on re-introduction of FODMAP containing foods.
Dietary supplementation with maltodextrin 5 grams twice daily for a month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Moderate or substantial improvement in irritable bowel syndrome (IBS) symptoms on IBS-GIS
Time Frame: 1 month after start of diet
|
The IBS-GIS (Irritable Bowel Syndrome Global Improvement Score) is a validated 7-point balance scale to assess change in perception of symptoms in functional bowel disorders.
Points 6 and 7 on the scale refer to moderate or substantial improvement.
The outcome measure will be the proportion of participants in each group marking point 6 or 7 on the balance scale at this time point.
|
1 month after start of diet
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Moderate or substantial improvement in IBS symptoms
Time Frame: 6 months after star of diet
|
The IBS-GIS (Irritable Bowel Syndrome Global Improvement Score) is a validated 7-point balance scale to assess change in perception of symptoms in functional bowel disorders.
Points 6 and 7 on the scale refer to moderate or substantial improvement.
The outcome measure will be the proportion of participants in each group marking point 6 or 7 on the balance scale at this time point.
|
6 months after star of diet
|
Adequate control of IBS symptoms
Time Frame: 1 month after start of diet
|
Response to a yes/no question "Have your symptoms been adequately controlled?"
|
1 month after start of diet
|
Adequate control of IBS symptoms
Time Frame: 6 months after start of diet
|
Response to a yes/no question "Have your symptoms been adequately controlled?"
|
6 months after start of diet
|
Percentage of days with loose stool
Time Frame: during last 14 days of dietary intervention
|
Percentage of days with at least one stool of consistency type 6 or 7 on the Bristol stool form scale
|
during last 14 days of dietary intervention
|
Change from baseline in IBSS
Time Frame: 1 month after start of diet
|
The IBSS (Irritable Bowel Symptom Severity Scale) is a validated composite score of symptoms in functional intestinal disorders
|
1 month after start of diet
|
Change from baseline in IBSS
Time Frame: 6 months after start of diet
|
6 months after start of diet
|
|
Change from baseline in fasting colonic volume
Time Frame: 1 month after start of diet
|
This is a mechanistic endpoint.
Colonic volume will be assessed by Magnetic Resonance Imaging at baseline and after intervention.
|
1 month after start of diet
|
Change in fasting colonic gas volume
Time Frame: 1 month after start of diet
|
This is a mechanistic endpoint.
Colonic gas volume will be assessed by Magnetic Resonance Imaging at baseline and after intervention.
|
1 month after start of diet
|
Change from baseline in stool concentration of Bifidobacteria
Time Frame: 1 month after start of diet
|
This is a mechanistic endpoint, to assess changes in the microbiota caused by dietary intervention
|
1 month after start of diet
|
Change from baseline in stool concentration of Bifidobacteria
Time Frame: 6 months after start of diet
|
This is a mechanistic endpoint, to assess changes in the microbiota caused by dietary intervention
|
6 months after start of diet
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in EQ-5D-5L score
Time Frame: 1 month after start of diet
|
The EQ5D is a validated questionnaire to measure quality of life
|
1 month after start of diet
|
Change from baseline in EQ-5D-5L score
Time Frame: 6 months after start of diet
|
6 months after start of diet
|
|
Change from baseline in stool concentration of short-chain fatty acids
Time Frame: 1 month after start of diet
|
1 month after start of diet
|
|
Change from baseline in stool concentration of short-chain fatty acids
Time Frame: 6 months after start of diet
|
6 months after start of diet
|
|
Change from baseline in other clades of stool microbiota
Time Frame: 1 month after start of diet
|
This will be exploratory work to assess the effect of the diet on other constituents of the stool microbiota
|
1 month after start of diet
|
Change from baseline in other clades of stool microbiota
Time Frame: 6 months after start of diet
|
6 months after start of diet
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Giles AD Major, BM BCh MRCP, University of Nottingham
- Study Chair: Robin C Spiller, PhD FRCP, University of Nottingham
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UoN14048
- 14GA012 (OTHER: Nottingham University Hospitals NHS Trust)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Functional Gastrointestinal Disorders
-
Umeå UniversityRecruitingFunctional Gastrointestinal DisorderSweden
-
The University of Texas Medical Branch, GalvestonCompletedGastrointestinal Disorders, Functional
-
Dr Anne PayneUniversity of LondonUnknownFunctional Gastrointestinal Disorders in ChildrenUnited Kingdom
-
Chang Gung Memorial HospitalNew Bellus EnterprisesUnknownNeoplasm | Functional Gastrointestinal DisorderTaiwan
-
BayerCompletedA Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world SettingFunctional Dyspepsia | Irritable Bowel Syndrome | Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional DyspepsiaGermany
-
Chinese University of Hong KongCompletedFunctional Gastrointestinal DisorderHong Kong
-
Aarhus University HospitalKarolinska InstitutetCompletedFunctional Gastrointestinal DisordersDenmark
-
Bausch Health Americas, Inc.CompletedFunctional Gastrointestinal DisordersUnited States
-
Danone Asia Pacific Holdings Pte, Ltd.ObvioHealthCompletedFunctional Gastrointestinal DisordersThailand
-
BayerCompletedFunctional Gastrointestinal DisordersGermany
Clinical Trials on low FODMAP dietary advice
-
Sahlgrenska University Hospital, SwedenCompletedIrritable Bowel SyndromeSweden
-
Weizmann Institute of ScienceNot yet recruitingIrritable Bowel Syndrome
-
University of GaziantepCompletedIrritable Bowel SyndromeTurkey
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Oh Yoen KimDong-A UniversityCompleted
-
Vendsyssel HospitalCompleted
-
Ashok TutejaUnited States Department of DefenseUnknown
-
Beth Israel Deaconess Medical CenterEnrolling by invitation
-
Ohio State UniversityCompletedAutism Spectrum DisorderUnited States
-
University of NottinghamKing's College LondonCompletedIrritable Bowel SyndromeUnited Kingdom